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1Division of Immunology, Beckman Research Institute of the City of Hope, Duarte, CaliforniaABSTRACT G-protein-coupled receptors (GPCRs) are membrane proteins that allosterically transduce the signal of ligand
binding in the extracellular (EC) domain to couple to proteins in the intracellular (IC) domain. However, the complete pathway
of allosteric communication from the EC to the IC domain, including the role of individual amino acids in the pathway is not
known. Using the correlation in torsion angle movements calculated from microseconds-long molecular-dynamics simulations,
we elucidated the allosteric pathways in three different conformational states of b2-adrenergic receptor (b2AR): 1), the inverse-
agonist-bound inactive state; 2), the agonist-bound intermediate state; and (3), the agonist- and G-protein-bound fully active
state. The inactive state is less dynamic compared with the intermediate and active states, showing dense clusters of allosteric
pathways (allosteric pipelines) connecting the EC with the IC domain. The allosteric pipelines from the EC domain to the IC
domain are weakened in the intermediate state, thus decoupling the EC domain from the IC domain and making the receptor
more dynamic compared with the other states. Also, the orthosteric ligand-binding site becomes the initiator region for allosteric
communication in the intermediate state. This finding agrees with the paradigm that the nature of the agonist governs the specific
signaling state of the receptor. These results provide an understanding of the mechanism of allosteric communication in class A
GPCRs. In addition, our analysis shows that mutations that affect the ligand efficacy, but not the binding affinity, are located in
the allosteric pipelines. This clarifies the role of such mutations, which has hitherto been unexplained.INTRODUCTIONG-protein-coupled receptors (GPCRs) are seven helical
transmembrane (TM) proteins that mediate intracellular
(IC) signaling and form the largest class of drug targets.
GPCRs act as allosteric machines in communicating the
event of ligand binding in the extracellular (EC) domain to
the IC domain to initiate the coupling of effector proteins.
Binding of an agonist or an inverse agonist leads to stabiliza-
tion of specific conformational states of the GPCR, and bind-
ing of both an agonist and a G-protein stabilizes the receptor
in the fully active state, as evidenced by recently published
crystal structures (1–6). The key question of how the ligand
binding in the EC domain is communicated to residues in
the IC domain has not been completely answered and is diffi-
cult to resolve from experiments. Allosteric modulators that
modulate (increase or decrease) the activity of the orthosteric
agonist are emerging as a cutting-edge strategy in drug design
for GPCRs (7). Many allosteric modulators affect activation
without any direct contact with the orthosteric agonist or the
G-protein site. Oneway thesemodulators could affect activa-
tion is by interacting with the residues that mediate allosteric
communication between the orthosteric and the G-protein
site. Mapping the allosteric communication pathways in
GPCRs would thus provide insights into allostery and aid
the discovery of allosteric modulators.Submitted February 10, 2014, and accepted for publication June 9, 2014.
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0006-3495/14/07/0422/13 $2.00In class A GPCRs, the distance between the orthosteric
ligand binding site and the signaling protein coupling site
is >30 A˚ (3). Therefore, allosteric communication plays a
vital role in propagating the activation signal from the or-
thosteric site to the IC region of the receptor. Biophysical
experiments have provided insights into the activation
mechanism of mainly class A GPCRs, such as rhodopsin
and b2 adrenergic receptor (b2AR) (8,9). It has been pro-
posed that minor perturbations at the agonist-binding site
are transmitted to the IC interface via intermediate residue
contacts (10,11). This hypothesis is corroborated by the
fact that mutations of residues distant from both the
ligand-binding site and the G-protein interface affect recep-
tor activation. The role of such mutations is not well under-
stood. Here, we used mutual information (MI) in internal
coordinates, calculated from microseconds-long, all-atom
molecular-dynamics (MD) simulations of human b2AR in
explicit membrane and water, to elucidate the allosteric
communication pathways.
Computational approaches for mapping allosteric net-
works in proteins range from bioinformatics (12,13) to
elastic network models (14,15), analysis of contact maps
(16), force distribution (17), and correlated residue motions
(18–22). One drawback of bioinformatics-based methods,
such as evolutionary trace analysis, is that they cannot
distinguish functional residues from those that govern struc-
tural stability. Previous studies used correlated residue
motions to map allosteric networks in soluble proteins byhttp://dx.doi.org/10.1016/j.bpj.2014.06.015
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from MD simulations. MI-based network analyses with
accelerated MD (AMD) trajectories were used to map allo-
steric communication between the ligand-binding site and
G-protein site of the M2 muscarinic acetylcholine receptor
(M2-AcR), a class A GPCR (22). The use of Cartesian co-
ordinates in the above works could introduce noise into
the correlation calculation due to high-frequency motions
(18,20), leading to spurious correlations among allosteric
residues. Here, we used correlations in the torsional space,
which eliminates high-frequency noise (20).
In this work, we derived the allosteric communication
pathways for inactive and active conformations of human
b2AR using correlations in torsion angle movements (calcu-
lated using MI) obtained from long-timescale MD trajec-
tories. When multiple allosteric communication pathways
show significant overlap, they form what we term allosteric
pipelines. The residues in the pipeline through which multi-
ple pathways pass are termed allosteric hubs. Our main
goals in this work were to (1), investigate the role of allo-
steric pipelines in conferring stability to inactive and active
states of the receptor; (2), identify allosteric hub residues
that play an important role in allosteric communication;
and (3), identify allosteric sites that can aid in the design
of allosteric modulators (7).MATERIALS AND METHODS
Description of the MD protocol
The MD trajectories for the three states of b2AR, i.e., starting from the crys-
tal structures of the inactive state, the active state with the nanobody (G-pro-
tein mimic) removed, and the nanobody-bound active state, were obtained
from DE ShawResearch (23,24). Inactive-state simulations were performed
for 16 ms on the inactive b2AR crystal structure (Protein Data Bank (PDB)
ID: 2RH1) bound to the inverse agonist carazolol. Active-state simulations
(5.9 ms) were performed on the active b2AR crystal structure (PDB ID:
3P0G) bound to nanobody and the agonist BI-167017. Some of the simula-
tions that were started from the active-state structure (3P0G), but with the
nanobody removed, showed a collapse of the structure to the inactive state.
These simulations showed a pathway to the deactivation of the receptor. We
extracted the ensemble for the agonist-bound intermediate state from these
simulations as detailed in Text S1 of the Supporting Material. All simula-
tions were performed in the presence of palmitoyl oleoyl phosphatidyl
choline (POPC) lipids, water, and ions using the CHARMM27 force field
(25) on the ANTON supercomputer.Calculation of allosteric pathways
We calculated the MI using the torsional degrees of freedom as described in
Text S2. We calculated allosteric pathways between each pair of residues
that showed above-average MI (MI > MIavg) and were >10 A˚ apart in
the receptor structure. We first constructed an undirected graph using inter-
residue contacts, where the residues formed nodes and the interresidue
contacts formed the edges of the network. An interresidue contact was iden-
tified if the Ca atoms of the residue pair were within 10 A˚ of one another.
The edge weights were calculated as MImax – MIab, where MImax is the
maximumMI among all residue pairs in the receptor and MIab is the MI be-
tween the terminal residues of the edge. Moreover, to avoid selecting path-ways with weak MI, the weights of all edges with MI < MIavg were set to
zero. For a given residue pair, the allosteric pathway is defined to be the
connecting route between the two residues, which minimizes the number
of intermediate nodes and maximizes the sum of edge MIs of the connect-
ing route. The allosteric pathways were calculated using the shortest-path
algorithm by Dijkstra (26), as implemented in the Bioinformatics ToolBox
in MATLAB (The MathWorks, Natick, MA).Clustering of allosteric pathways into pipelines
The allosteric pathways were sorted by the MI between their termini resi-
dues, and the top 500 pathways were selected for further analysis. These
pathways were clustered based on their mutual proximity in the receptor
structure. To define the proximity of two pathways, we defined a parameter
called overlap, which is the fraction of nodes of both pathways that are
within a cutoff distance (10 A˚) of one another. Thus, nearby pathways
have strong overlap and distant pathways have zero overlap. Using overlap
as a similarity metric, we clustered the pathways using the hierarchical clus-
tering routine in MATLAB. To determine the optimal number of clusters,
we calculated 1), intraoverlap, defined as the average overlap between
pathways within each cluster; and 2), interoverlap, defined as the average
overlap between clusters. The optimal number of clusters was chosen as
that which maximized intraoverlap while minimizing interoverlap. More
details regarding the clustering procedure are given in Text S3 and Fig. S8.RESULTS
We calculated the allosteric pipelines from theMI calculated
from extensive MD simulations of three distinct conforma-
tional states of b2AR: 1) the inactive state of the receptor
bound to the inverse agonist carazolol; 2) agonist-bound
b2AR, a highly dynamic state that is referred to as the inter-
mediate state (10,11) because it is on the activation pathway
to the fully active state; and 3) the fully active state of b2AR
with both the full agonist BI-167017 and aG-proteinmimetic
nanobody bound. For details regarding these MD trajec-
tories, see the Materials and Methods section.
We first characterized the number and nature of the sub-
states present in the ensemble of the three MD trajectories.
Analysis of crystal structures of the active (PDB ID: 3SN6)
and the inactive (PDB ID: 2RH1) states of b2AR showed a
movement of the IC end of TM6 away from TM3 in going
from the inactive state to the active state. To characterize
the ensemble of substates sampled in the MD simulations
of the inactive, intermediate, and fully active states of
b2AR, we compared the distance between the IC ends of
TM3 and TM6 (shown in Fig. 1 A) among the different sub-
states, as well as the root mean-square deviation (RMSD) of
the NPxxY motif on TM7 from the inactive state (Fig. S1 f)
(24). Fig. 1 B shows the distribution of the distance between
TM3 and TM6 for the inactive, intermediate, and active
states from the three ensembles. Whereas the active- and
inactive-state receptors show sharper peaks close to their
respective crystal structures, the intermediate agonist-bound
state has a broader distribution of TM3–TM6 distance, with
a peak in between the inactive and active states. Also in the
intermediate state, the NPxxY motif assumes an inactive-
like conformation (Fig. S1 f). The broad distribution ofBiophysical Journal 107(2) 422–434
FIGURE 1 (A) The TM3–TM6 distance is
measured between the geometric centers of the res-
idues highlighted in orange on TM3 and TM6. Due
to the high flexibility of helical ends, the last four
residues from the IC end of each helix were
excluded from the geometric center calculation.
(B) Population distributions of TM3–TM6 distance
in simulations of the inactive (blue), intermediate
(green), and active (red) states. This distance
in the crystal structures of the inactive (PDB ID:
2RH1) and G-protein-bound active (PDB ID:
3SN6) states are shown by dotted lines. (C)
Average interdihedral MI as a function of the pair-
wise interdihedral distance. A dihedral is defined
as a set of four sequentially bonded atoms that
form a torsion angle. The interdihedral distance
is the distance between the geometric centers of
two dihedrals. (D) Average MI and ratio of allo-
steric to direct contact MI for different b2AR
states. To see this figure in color, go online.
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with the finding that the order parameter from NMR studies
of b2AR showed lower order for the intermediate state than
for the active or inactive state (10). We also decomposed the
distance distribution for each state into its component
Gaussian distributions (Fig. S1). The inactive- and active-
state distance distributions show populations around two
distinct substates, representing the peaks in the individual
Gaussians, whereas the intermediate state shows three
substates (Fig. S1). The high number of substates further
demonstrates the dynamic nature of the agonist-bound inter-
mediate state. Using this ensemble of states, we calculated
the MI in torsional space as described in the Materials and
Methods section and Text S2.The inactive state shows more correlated
movement of residues than the intermediate and
active states
We identified the pairs of residues that showed strong allo-
steric communication (sorted by their strength of MI). Fig. 1
C shows the time-averaged MI in torsion angles for all tor-
sion pairs as a function of the intertorsion distance (i.e., the
distance between the geometric centers of the two torsional
angles; also see Text S4). The higher the MI value in torsion
angles, the greater is the correlated movement of the atoms
that make up the two torsion angles. If the two torsions in a
pair are neighbors (within 5 A˚), the correlated movement
will be high, as would be expected due to the direct contact
of the atoms in the two torsions. Beyond 5 A˚, the intertor-Biophysical Journal 107(2) 422–434sion MI decreases, but then rises slowly beyond 10 A˚.
Therefore, the trend shown in Fig. 1 C is evidence of the
presence of allosteric communication in these dynamic tra-
jectories of b2AR. The allosteric long-distance communica-
tion is weakest in the intermediate state and increases in
both the inactive and active states. We quantified the average
MI in different receptor states using the ratio of the allosteric
MI to the direct MI in Fig. 1 D. It is evident from this figure
that the intermediate state shows both lower direct MI and
allosteric MI, and therefore the residue movements are
more uncorrelated, leading to a more dynamic state of the
receptor. This is in agreement with the recent NMR results
for b2AR that show that the agonist-bound intermediate
state is more dynamic than the inactive or active state of
b2AR (10,11).Allosteric communication pathways, or allosteric
pipelines
For a residue pair with a high level of correlated movement
(e.g., residues A and B), we calculated the shortest allosteric
communication pathway to get from residue A to B while
also maximizing the MI in this pathway, using graph theory
algorithms as described in Materials and Methods. Here-
after, residues A and B are referred to as termini. By map-
ping the pathways between all distant (Ca-Ca distance >
10 A˚) residue pairs that have MI above a certain cutoff
(top 500 sorted by the calculated MI), we constructed a
network of allosteric pathways in each conformational state
of b2AR. Allosteric pathways that connected the same
Allosteric Pipelines in GPCR Activation 425termini with a high overlap (see Materials and Methods)
were clustered into channels, which we term allosteric pipe-
lines. Fig. 2, A–C, show the different allosteric pipelines
in the inactive, intermediate, and active conformations of
b2AR. The thickness of each pipeline is proportional to
the number of overlapping allosteric communication
pathways. To validate the statistical significance of the dif-
ferences in allosteric communication pipelines among the
three b2AR conformations, we analyzed MD trajectories
of control simulations. We compared the allosteric pipelines
calculated from two MD simulations starting from the same
receptor conformation and with just one residue changed.
The two simulations started from the crystal structure of
the inactive state (PDB ID: 2RH1) with a single residue
D1303.49 protonated (neutral) and deprotonated (charged)
(Fig. S2). These two simulations reflect the effect of
mutating a charged residue to a neutral one. In these two
simulations, the top-scoring allosteric pipeline is the same
as that shown in Fig. S2. However, there are other, thinner
pipelines connecting D1303.49 that show differences be-
tween the two simulations. This is to be expected due to
the change of the charged residue to a neutral residue.
A comparison of the number of allosteric communication
pathways in each pipeline in the three conformational states
of b2AR is shown in Table S1. For a given allosteric pipe-
line, the termini residues of the pathways that are close to
one another can be clustered together into termini patches
of residues. Thus, the EC residues form a terminus patch
communicating with the patch of residues in the G-pro-
tein-coupling site, and there could be one thick allostericpipeline connecting these two patches of residues. This
concept is illustrated in Fig. S3.Comparison of the allosteric pipelines for the
three conformational states of the b2AR
Among the inactive, intermediate, and active states of the re-
ceptor, the allosteric pipelines are thickest for the inactive
state, followed by the active and intermediate states (shown
in Fig. 2, A and C). In the inactive state, a thick allosteric
pipeline passes through TM6 (green pipeline in Fig. 2 A),
stabilizing it against independent movement and thus keep-
ing the receptor in the inactive conformation. This allosteric
pipeline is absent in the intermediate and active states
(Fig. 2, B and C). The IC end of TM6 becomes less corre-
lated with the rest of the receptor upon agonist binding,
facilitating activation. The narrow but distinct pipeline
that passes through TM6 in the active state (gray pipeline
in Fig. 2 C) could stabilize the receptor in the active confor-
mation. The active and intermediate conformations show
thick pipelines passing through TM7 (cyan and blue pipe-
lines in Fig. 2, B and C, respectively), which indicates that
TM7 is increasingly correlated in the active state, unlike
TM6, which is more dynamic. In the crystal structures of
active b2AR and rhodopsin (3,27), the IC part of TM7 is ori-
ented closer to the receptor core compared with the inactive
state, facilitating the outward tilt of TM6. The blue pipeline
could thus stabilize TM7 in the active-like conformation.
The intermediate and active states of the receptor also
show fairly thick allosteric pipelines (shown in cyan andFIGURE 2 (A–C) Comparison of allosteric
pipelines in three conformational states of b2AR.
(A) Inverse agonist-bound inactive state. (B)
Agonist-bound intermediate state. (C) Agonist-
and nanobody-bound active state. Each allosteric
pipeline is colored differently and the thickness
of the pipeline is proportional to the number of
allosteric pathways included in it. The number of
pipelines and quantitative details are given in Table
S1. (D) Schematic view of b2AR showing the dif-
ference in allosteric communication between the
inverse agonist-bound inactive and agonist-bound
intermediate states. The colored arrows indicate
significant differences in allosteric pathways
among the different functional domains (e.g., or-
thosteric binding site and G-protein interface).
The red arrow indicates an increase in the number
of allosteric pathways going from the inactive to
the agonist-bound state, and the blue arrow denotes
a decrease in allosteric communication between
the two states. To see this figure in color, go online.
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ing site to helix 8. This is a putative b-arrestin or G-pro-
tein receptor kinase-mediated allosteric pipeline that
requires further verification from experiments. The putative
b-arrestin-mediating allosteric pipeline (cyan pipeline in
Fig. 2 B) connecting the agonist-binding pocket with the
C terminus is the thickest in the intermediate state. Also,
the allosteric pipelines connecting the agonist-binding
pocket with the G-protein interface are weakened in the in-
termediate state compared with the inactive state. These two
observations are in agreement with recent NMR studies that
showed that conformational coupling between the agonist-
binding site and the G-protein interface is weakened in
the intermediate state (11). Moreover, the conformational
heterogeneity of the intermediate state could facilitate
signaling through multiple signaling pathways. In our
observations, the cyan pipeline in the intermediate state
could facilitate such noncanonical signaling pathways. To
compare the allosteric pipelines among the inactive, inter-
mediate, and active states, we plotted the population of
each pipeline in decreasing order of magnitude (Fig. S4;
Table S1). Whereas the pipeline population in the inactive
state showed a rapid decay with the number of pipelines,
both the intermediate and active states showed slower de-
cays. Thus, the inactive state shows fewer allosteric pipe-
lines, but each pipeline has a higher population than those
in the active state. The intermediate and active states show
increased numbers of allosteric pipelines, but each pipeline
has a lower population than the inactive-state pipelines.
Additionally, the pipelines in the intermediate state show
less correlated movement compared with both the inactive
and active states, as shown in Fig. 1 D. Thus, the intermedi-
ate state with just an agonist bound is a more dynamic state,
which shows an overall decrease in correlated movement
within the receptor. We also observed the presence of an
allosteric pipeline connecting the residues within the IC re-
gions (as shown in blue in Fig. 2 A), which was more domi-
nant in the inactive state of the receptor compared with the
intermediate agonist-bound state. This allosteric pipeline
could be useful for maintaining the IC regions in a tight
conformation to prevent the G-protein binding to the inac-
tive state of the receptor. We also observed such IC allosteric
pipelines in the fully active state, possibly to retain the
bound G-protein (28).
To identify which specific regions of the receptor show
correlated movement in the three states, we partitioned the
receptor into five regions: 1), the EC loop region; 2), the
EC part of the TM region; 3), the orthosteric ligand-binding
site; 4), the IC part of the TM region; and 5), the IC loop
region. These different regions are shown in Fig. 2 D. We
calculated the difference in the number of allosteric commu-
nication pathways in the inactive-state ensemble to the inter-
mediate-state ensemble, as shown in Fig. 2 D and Table S2.
The red arrows show an increase in the number of allosteric
pathways in the intermediate agonist-bound state comparedBiophysical Journal 107(2) 422–434with the inactive state, and the blue arrows show a decrease.
In the inactive state of the receptor, the allosteric pipelines
are initiated by residues in the EC loop region and termi-
nated by residues in the IC loop regions, thus transmitting
the signal through pipelines that keep the receptor intact
in the inactive state. However, when an agonist is bound to
the orthosteric site, the residues in the orthosteric ligand-
binding site become the initiators of allosteric communica-
tion to other parts of the receptor, as shown by the red arrows
emerging from the ligand-binding site to the EC and IC re-
gions. Simultaneously, there is a weakening of allosteric
communication between the EC loops and EC part of the
TM region with the G-protein-coupling site. Thus, in the
intermediate state, the top half of the receptor becomes de-
coupled from the bottom half of the receptor, and the recep-
tor becomes more dynamic than in either the active or
inactive state. The intermediate state was observed to be dy-
namic with a low order parameter in recent NMR measure-
ments on agonist-bound b2AR (10). Also in the intermediate
state, the G-protein-binding region becomes decoupled from
the rest of the receptor and thus acquires additional flexi-
bility, possibly to facilitate the insertion of G-protein.Mutations that affect the ligand efficacy, but not
the binding affinity, are identified to be in the
allosteric pipelines in b2AR
Several single-point mutations that are distant from the or-
thosteric ligand-binding site but show a substantial increase
or decrease in agonist-mediated receptor activation (or
constitutive activation) were observed previously in experi-
ments, but the mechanism by which these residues affect the
ligand efficacy has hitherto remained unexplained. These
mutations and the references from which they were taken
(along with the mutation positions that have been shown
to increase the thermostability of a specific inactive or active
state of the receptor on avian b1AR and human adenosine
A2A receptors (29,30)) are shown in Table S3. The criteria
for selecting the mutation data are explained in Text S5.
We observed that many of these mutations are located along
the major allosteric pipelines in one of the three functional
states of b2AR. There are experimental mutations leading to
inactivation or constitutive activity of the receptor that are
not located in the allosteric pipelines or near any of the allo-
steric pipelines. These mutations could not be explained by
the allosteric model, possibly because mutated receptors can
give rise to newer allosteric pipelines that are not predicted
using MD simulations on the wild-type receptor. The resi-
dues from Table S3 are highlighted in Fig. 3, A and B.
Fig. 3, A and B, shows the activating and deactivating muta-
tions and the allosteric pipelines mediated by these residues
in the inactive and active states, respectively. We postulated
that residues that show a decrease in agonist efficacy upon
mutation should stabilize the active state of the receptor,
and residues whose mutations increase the agonist efficacy
FIGURE 3 (A) Positions of mutations in the
literature that increase the agonist-mediated activa-
tion, constitutive activity, or thermostability of the
active state in class A GPCRs. The associated allo-
steric pipelines in the inactive state are shown. (B)
Mutations that suppress receptor activation or ther-
mostabilize the inactive state and the associated
allosteric pipelines in the active state. (C) Number
of pathways mediated through each mutation posi-
tion in b2AR in the three conformations. Green
bars represent activating mutations and red bars
represent inactivating mutations. (D and E) Loca-
tion of residues that increase receptor activation
upon mutation and the number of pathways medi-
ated through these residues in the (D) inactive and
(E) active states. (F and G) Locations of inactivat-
ing mutations and the number of pathways medi-
ated in the (E) inactive and (F) active states. To
see this figure in color, go online.
Allosteric Pipelines in GPCR Activation 427should stabilize the inactive state of the receptor. For a given
state of the receptor, we identified the residues that mediate
multiple pathways in each allosteric pipeline, i.e., the allo-
steric hubs. Fig. 3 C shows the number of allosteric path-
ways that pass through the residues listed in Table S3. To
test the robustness of these results (if the experimental mu-
tations listed in Table S3 can be placed near any arbitrary
pipeline), we reshuffled the residue pairwise MI andcomputed allosteric pipelines using the reshuffled MI matrix
(Fig. S5 A). Fig. S5 B shows the allosteric hub score (the
number of allosteric pathways mediated) of each residue
in the receptor for both the true allosteric pipelines and
the pipelines computed using the reshuffled MI (termed ran-
domized pipelines in the figure). All of the experimentally
mutated residues show significantly higher allosteric hub
scores for the true pipelines compared with the randomizedBiophysical Journal 107(2) 422–434
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near the allosteric pipelines is a significant observation.
Seven out of nine mutations that increase the agonist-
induced activation, constitutive activity, or thermostability
of the active state in class A GPCRs (L2.46, V2.52, F3.27,
I3.40, L3.43, S4.53, and F6.44) are located near major
allosteric pipelines in the inactive state. Here, we used the
Ballesteros-Weinstein residue numbering system for class
A GPCRs (31). The first number is the TM helix in which
the amino acid is present and the second number is the
position of this residue with respect to the most conserved
residue in that helix, which is numbered 50. Both L2.46
and V2.52 are located close to D2.50, which is a highly
conserved residue in class A GPCRs and is known to be
a sodium-binding site (allosteric modulator) in the high-
resolution adenosine A2A receptor crystal structure (32).
Residues I3.40, L3.43, F6.44, and M6.41 form a tight hydro-
phobic cluster in the middle of the TM region in inactive
b2AR (4). These residues mediate major allosteric pipelines
in the inactive state of b2AR. In a1BAR, mutating S4.53 to
Ala increased inositol phosphate accumulation by 125%
without affecting agonist binding. The number of allosteric
communication pathways mediated by residues L2.46,
V2.52, F3.27, I3.40, L3.43, S4.53, and F6.44 is higher in
the inactive state of b2AR, showing that these residues,
which are farther away from the ligand-binding site, stabi-
lize the inactive state by mediating allosteric communica-
tion. Eight out of 13 mutations that reduce the activity of
the receptor show an increase in the number of allosteric
pathways in the intermediate or active state compared
with the inactive state. Among these residues, T2.37,
Y5.58, G7.42, N7.49, and Y7.53 show high allosteric
involvement in the active state, whereas T4.56, C6.47, and
L7.38 show high allosteric involvement in the intermediate
state. The former set of residues could be important for sta-
bilizing the active state once the G-protein binds, and the
latter set could be involved in triggering the conformational
changes upon agonist binding that lead to activation. Exper-
imentally, mutating both sets of residues leads to a reduction
in receptor activation. Five of the 13 inactivating mutations
(M2.53, E3.41, L6.37, I7.41, and L7.51) show increased
allosteric pathway involvement in the inactive state, which
suggests that the mutations should stabilize the active state.
Experimentally, however, these mutations all lead to loss
of activity of the receptor. E3.41 is located in the middle
of TM3 facing TM4. Mutating this residue to Trp increases
the thermostability of the inactive state of b2AR (33).
Mutating L6.37 to Ala increases agonist-induced activation
in a1bAR (34). Both E3.41 and L6.37 mediate allosteric
pathways in all three conformational states in b2AR, with
higher involvement in the inactive state. Thus, mutating
E3.41 or L6.37 can affect the stability of both the inactive
and active states. L7.51 is part of the highly conserved
NPxxY motif on TM7, which changes conformation by
moving inward upon activation. The NPxxY motif is moreBiophysical Journal 107(2) 422–434involved in allosteric communication in the intermediate
and active states compared with the inactive state (Fig. 2,
A–C). Thus, mutating any residue in the NPxxY region
could adversely affect activation. In contrast, the roles of
M2.53 and I7.41 are less clear. Mutating M2.53 to Leu in-
creases the thermostability of the inactive state in b1AR.
In recent NMR studies, M2.53 was shown to switch between
multiple rotameric states in the inactive state of b2AR, and
these transitions were suggested to occur on a millisecond
timescale (11). Therefore, microseconds of MD simulations
may not be sufficient to reproduce allosteric correlations
involving M2.53. The effect of mutating I7.41 was weak.
In b1AR, mutating I7.41 to Ala slightly increased antagonist
binding, and no activation data were reported.
Fig. 3 D shows several mutations that increase the activity
of the receptor, namely, L2.46, I3.40, L3.43, S4.53, andF6.44,
and the associated allosteric pathways in the inactive state of
b2AR, and Fig. 3E shows similar pathways in the active state.
These residues are mainly located on TM3 and TM6 and they
form a tight hydrophobic cluster that stabilizes the inactive
state. The number of pathways mediated by these residues
is higher in the inactive state compared with the active state.
This explains why mutating these residues leads to increased
activation of the mutant receptors. In contrast, many of the in-
activatingmutations are located onTM7, as shown in Fig. 3,F
and G. These residues mediate an increasing number of allo-
steric pathways in the intermediate and active states compared
with the inactive state. Thus, our analysis shows that muta-
tions that affect the ligand efficacy, but not thebinding affinity,
are located in the allosteric communication pathways. Thus,
our findings provide insights into the role of such mutations,
which has hitherto been unexplained.Role of residues in the orthosteric site in the
allosteric communication pathways
We first identified the binding-site residues that are present
in the orthosteric binding site of the agonist BI-167017 and
the inverse agonist carazolol. The next step was to identify
which of these residues are also major participants in allo-
steric communication by calculating the number of path-
ways mediated by these residues. Fig. S6, A–D, show the
binding-site residues and the allosteric communication path-
ways they mediate in the intermediate state of the receptor.
We chose the agonist-bound intermediate state because this
is the state that is dynamic and is in the pathway to full acti-
vation. Fig. S6, E–H, show the binding-site residues that
mediate more allosteric communication pathways in the
active state compared with the inactive state. T195 in EC
loop 2 (ECL2) is placed directly above the orthosteric
ligand-binding site. This residue is located in multiple allo-
steric pathways of the intermediate state that connect the EC
loop region to the G-protein-coupling region. T195 is also
located in the allosteric pathway of the active state that con-
nects the EC region to helix 8, which is part of the carboxy
Allosteric Pipelines in GPCR Activation 429terminus that couples to b-arrestin (35). T1103.29, which
is located in the agonist-binding site one turn above
D1133.32, is involved in extensive allosteric networks
involving the EC loops and the G-protein-coupling region
(Fig. S6 B). The other two residues that show allo-
steric pathway involvement in the intermediate state are
Y3167.43 and S2075.46. Y3167.43 is also involved in allosteric
communication in the active state. This residue directly in-
teracts with the agonist by forming a hydrogen bond with
the protonated amine of the ligand. Our observation explains
why the mutation of these residues affects the receptor
activity (36,37). S2045.43 shows allosteric activity in the
active state. S2035.42 and S2075.46 are major agonist con-
tacts in b2AR
2 (2,3). S2045.43 does not contact the agonist
directly and instead forms a hydrogen bond with N2936.55.
When mutated to nonpolar amino acids, both S2035.42 and
S2045.43 impair the binding and activity of catecholamine
agonists (38,39). F2896.51 and F2906.52, located in the or-
thosteric site, form aromatic packing with the biphenyl/cate-
chol moieties of b2AR agonists. Mutating F289
6.51 to Ala
and F2906.52 to Met reduced agonist binding by 1000- and
10-fold, respectively, but did not affect antagonist binding
(40). These two residues are involved in allosteric commu-
nication with the G-protein-binding site in the active state.Identification of allosteric sites for finding
allosteric modulators
Designing allosteric modulators has become a current ther-
apeutic strategy for specifically targeting receptors with sub-type specificity (7,41). Computational methods can be used
to identify potential binding sites that are different from or-
thosteric sites in GPCRs (42). However, there is no method
to identify whether targeting these potential void spaces in
the protein would be effective for allosteric modulation.
We have shown in this work that mutation results could be
explained by identifying the allosteric hubs that mediate
multiple allosteric communication pathways, and the loca-
tion of these residues must be involved in allosteric commu-
nication. Any stable and significant void spaces that form
during the dynamics of the receptor and are close to these
allosteric hubs could be potential allosteric sites that can
be used to design allosteric modulators. Fig. 4 A shows all
of the void spaces (blue wireframe) that are detected in
the active-state crystal structure of b2AR (PDB ID: 3P0G)
and could accommodate small-molecule binders. All of
these sites are water accessible as well (Fig. S7). One of
these is the orthosteric site (shown in pink). All of the other
void spaces correspond to allosteric modulator binding
pockets observed in related class A GPCRs. These allosteric
pockets are interconnected by allosteric pipelines, shown in
Fig. 4 A. Right above the orthosteric site is the allosteric
binding site in M2-AcR (PDB ID: 4MQT) (43). In b2AR,
there are two major allosteric hubs that are located in this
region: F194ECL2 and T195ECL2 (Fig. 4 B). In addition, we
also identified five different void spaces that are distant
from the orthosteric agonist-binding site and located near
the G-protein interface (Fig. 4 C). One of these identified
sites (pocket 5) was previously verified experimentally
as the Zn2þ-binding site, with Zn2þ being an allostericFIGURE 4 (A) Allosteric pockets identified in
the active conformation of b2AR, along with the
allosteric pipelines that mediate communication
among them. The known allosteric binding sites
from other class A GPCRs are overlaid. These
include a Zn2þ-binding site in b2AR, Na
þ-binding
site in A2A adenosine receptor, and allosteric
modulator LY2119620 in M2-AcR. (B) Expanded
view of the allosteric region located in the EC
loops of b2AR, showing the key allosteric hub res-
idues. (C) Allosteric pockets near the G-protein
interface in b2AR. The residues that define these
pockets are highlighted. To see this figure in color,
go online.
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thosteric site and the other pockets are farther down. Pocket
2 is next to the NPxxY motif on TM7, pocket 3 is between
TM3 and TM7, and pocket 4 is near TM5 and TM6. Pocket
2 corresponds to the Naþ-binding site in the A2A adenosine
receptor (32), which was recently suggested to bind other
modulators, such as amiloride (45). Fig. 4 C also shows
the allosteric pipelines that are in close proximity to these
pockets. The potential small-molecule-binding pockets 2,
3, 4, and 5, which are modulated by the allosteric pipelines,
could be allosteric binding pockets. The allosteric hub resi-
dues that modulate the interactions of the allosteric pipe-
lines with these pockets are F2826.44, N3227.49, and
Y2195.58. Small-molecule modulators designed to bind to
these pockets could potentially enhance the activation of
b2AR because they could directly affect the allosteric pipe-
lines. Similar allosteric sites identified by this method could
be used to design or screen for allosteric modulators of
b2AR or other class A GPCRs.DISCUSSION
Among the three conformational states of b2AR (inactive,
active, and intermediate), the intermediate state shows
thinner allosteric pipelines than the inactive state and ex-
changes less MI among the TM residues compared with
the other two states. Thus, the intermediate state is more dy-
namic compared with the inactive or active state. The recep-
tor dynamics in the agonist-bound intermediate state reveals
molecular motion similar to the activation process, i.e.,
movement of TM5 and TM6 away from TM3 (10,46).
The decrease in correlated movement between the EC re-
gion and the G-protein-coupling site in the agonist-bound
intermediate state makes the IC interface flexible, thus facil-
itating insertion of the G-protein. The dynamic nature of theBiophysical Journal 107(2) 422–434intermediate state agrees with the observation that the orien-
tational order parameter observed in 19F NMR experiments
for b2AR is lower in the agonist-bound intermediate state of
b2AR compared with the other states (10).
When the receptor is in the inactive state, the allosteric
pipelines are initiated by residues in the EC regions and
they communicate to residues in the IC region of the recep-
tor as shown in Fig. 5 A. This keeps the receptor in the inac-
tive state, with minimal movement of TM6 away from TM3.
The involvement of the residues in the orthosteric ligand-
binding site in allosteric communication is minimal in
the inactive state, as depicted by the schematic picture in
Fig. 5 A. Binding of the agonist leads to residues in the
agonist-binding site, initiating allosteric communication to
the EC regions as well as IC regions of the receptor. In
this intermediate state, the agonist-binding site becomes
the command center, communicating with different parts
of the receptor. In the intermediate state, the receptor is de-
coupled into the top EC half and bottom IC half and be-
comes more dynamic, as shown in the schematic in Fig. 5 B.
To study the early events in the dynamics of the agonist-
bound receptor leading to activation, we analyzed the propa-
gation of allosteric signal from the orthosteric site to the
G-protein-coupling site in the agonist-bound intermediate re-
ceptor conformation. Fig. 6 A shows the allosteric network
near the orthosteric ligand-binding site in the intermediate
receptor conformation. T1103.29, S2035.42, S2075.46, and
Y3167.43 in the orthosteric site receive the allosteric signal
from the agonist-binding site and propagate it to several
residues located on TM3, TM5, TM6, and TM7. These
residues (I1213.40, E1223.41, L2125.51, F2826.44, C2856.47,
and F3217.48), which we call the connector region (marked
as connector 2 in Fig. 6D), are highlighted in Fig. 6A. Among
these six residues, I1213.40 and F2826.44 have also been
previously shown to have concerted rotamer motion in aFIGURE 5 Model of b2AR showing the dy-
namics and variation of allosteric pipelines in the
TM domains in the (A) inactive state and (B)
agonist-bound intermediate state. The diffusion
of agonist into the orthosteric site is schematically
depicted as the triggering event for the uncorre-
lated motions in the EC and IC domains of the
TM regions that lead to activation. The arrows
indicate the mode of dynamics of the TM regions
in the two states. In the inactive state, the strong
MI correlation between the EC and IC domains
suggests that the entire TM regions move as a
whole. While in the agonist-bound state, the EC
and IC domains move independently and their
motions are governed by the orthosteric site. To
see this figure in color, go online.
FIGURE 6 (A) Allosteric network of residues in
the intermediate state between the ligand-binding
site and connector residues in TM3, TM5, TM6,
and TM7. (B) Allosteric network in the active state
between TM5 and TM6. (C) Initiator domain in the
EC loops with the allosteric communication
network involving T195 shown by the orange lines.
The crystal structure of M2-AcR is overlaid for
comparison. (D) Residues involved in the mecha-
nism of agonist-mediated allosteric communica-
tion starting at the EC loops and ending at the IC
interface of b2AR. To see this figure in color, go
online.
Allosteric Pipelines in GPCR Activation 431microsecond-timescale dynamics simulation on nanobody-
bound active b2AR (24). Also, mutating C285
6.47 to Ser sup-
pressed activationwithout affecting agonist binding (47). The
allosteric model thus explains the effects of these residues.
The residues involved in the allosteric pipelines near TM5
and TM6 are distinctly different in the active state compared
with the intermediate state. In the intermediate state, the
IC domain of TM6 shows very little allosteric-correlated
movement. However, TM6 in the active conformation
shows a distinct allosteric pipeline that communicates
with TM5 (Fig. 6 B). We also observed that in the active
state, M2796.41 on TM6 allosterically communicates with
Y2195.58 and L2125.51 on TM5. While we were working
on this manuscript, allosteric networks for M2-AcR (22)
calculated using accelerated MD simulations were pub-
lished. In the MD simulations on M2-AcR apoprotein,
two major clusters of communicating residues were
observed: one involving TM3 and TM5, and the other
including TM6 and TM7. These two allosteric clusters
were connected through communication networks such
as Y2065.58–L3936.41, which correspond to Y2195.58 and
M2796.41 in b2AR, and P198
5.50–V1113.40, which corre-
spond to P2115.50 and I1213.40 in b2AR. Besides Y219
5.58
and M2796.41, I1213.40 forms a connector residue in our
calculations that receives the signal from the orthosteric
site. Thus, our results correlate with other simulation
results (22). Notably, in the M2-AcR crystal structure
(48), Y2065.58 (M2-AcR sequence numbering, which
is Y2195.58 in b2AR) interacts with the residues in the
VTIL motif on TM6, which is one turn below L3936.41
(M2796.41 in b2AR). It was shown by site-directed mutagen-
esis that the interaction of Y2065.58 with VTIL is critical
for G-protein selectivity (preference for Gi/o over Gq) (49).
Therefore, the allosteric network involving Y2195.58 and
M2796.41 is important not only for the stability of the G-pro-
tein-bound receptor conformation but also for the specificity
of the G-protein-coupling conformation.In the biogenic amine family of GPCRs, the EC loops
possibly form the ligand entry and exit domain. The EC loops
are widely speculated to contain a putative allosteric-modu-
lator-binding site; however, so far, only the muscarinic AcRs
have been found to bind allostericmodulators at this site (50).
In b2AR, the EC surface has been shown to react differently
to agonists and antagonists by modulating a salt bridge
between K3057.32 and D192ECL2 (51). It was proposed that
F193ECL2 next to D192ECL2 interacts directly with antago-
nists and thus propagates allosteric signal from the EC loops
to the orthosteric site. In our calculations, T195 in ECL2 is
a major initiator of allosteric communication in the inter-
mediate and active receptor conformations. T195ECL2 is
close to F193ECL2 and shows correlated torsion angle
motion with F193ECL2. In turn, F193ECL2 communicates
with T1103.29 andD1133.32 in the agonist-binding orthosteric
site (Fig. 6 C). To correlate the allosteric network of residues
we identified in ECL2with the allostericmodulator site spec-
ulated inM2-AcR, we overlaid theM2-AcR crystal structure
(PDB ID: 3UON) over b2AR (PDB ID: 3P0G) shown in
Fig. 6 C. We found that T195ECL2 and F193ECL2 are in the
same locations as F181ECL2 and Y177ECL2 in M2-AcR. In
microseconds of MD simulations with M2-AcR, the agonist
tiotropium transiently binds to an allosteric site consisting of
F181 and Y177 before diffusing into the orthosteric site (52).
Moreover, Y177 is a known key contact for modulating
agonist binding in M2-AcR (50) and breaking of the salt
bridge between K3057.32 and D192ECL2 in b2AR (51).
Also, in recent MD simulations by Dror et al. (53), the resi-
dues Y177ECL2, W4227.35, Y802.61, and Y832.64 were shown
to be themajor contacts for allostericmodulators inM2-AcR.
In b2AR, residue Y308
7.35 is located near major allosteric
hubs that communicate with the G-protein interface. How-
ever, residues G902.61 and H932.64 show more allosteric
involvement in the inactive state compared with the active
state. Together, these results indicate that allosteric commu-
nication originates at the EC loops at residues such asBiophysical Journal 107(2) 422–434
432 Bhattacharya and VaidehiT195ECL2, F193ECL2, and Y3087.35, propagating to the or-
thosteric site via V872.58, F892.60, T1644.56, and S1654.57,
which form the connector 1 region in Fig. 6 D. From here,
the communication signal reaches the distribution hub
in the orthosteric site consisting of T1103.29, S2035.42,
S2075.46, and Y3167.43. The signal is then distributed to
the connector 2 region consisting of I1213.40, E1223.41,
L2125.51, F2826.44, C2856.47, and F3217.48 (Fig. 6 D),
and communicated to L752.46 I1544.46, M2155.54, Y2195.58,
I2786.40, M2796.41, and Y3267.53 before terminating at the
G-protein-coupling region and helix 8 or the carboxy termi-
nus. Thus, a complete chain of communication exists be-
tween the EC loops and the G-protein-coupling region at
the IC interface, modulated in the middle by residues in
the agonist-binding orthosteric site. This is schematically
depicted in Fig. 6 D.CONCLUSIONS
In this work, we mapped the allosteric communication pipe-
lines in b2AR that transmit the activation signal from the or-
thosteric site to the IC interface of the receptor.We compared
the allosteric pipelines among three receptor states, termed
the inverse agonist-bound inactive, agonist-bound intermedi-
ate, and agonist- and nanobody (G-protein mimic)-bound
active states. Whereas the inactive state shows a few thick
allosteric pipelines, the intermediate and active states show
many thin pipelines. There is an overall decrease in allo-
steric-correlated movement between residues in the interme-
diate state, indicating the dynamic nature of the intermediate
state. The allosteric pipelines extend from the EC to the IC
regions, keeping the receptor in the inactive state. These pipe-
lines are weakened in the agonist-bound intermediate state,
with more pipelines emerging from the orthosteric ligand-
binding site to the rest of the receptor in this state. Thus,
the intermediate state is more dynamic than the inactive or
active state of the receptors. This increased dynamics would
be necessary to trigger the conformational changes in the
receptor that leads to activation.
We identified the key residues and residue networks
involved in the continuous communication pipelines from
the EC loops to the G-protein-coupling site that leads to re-
ceptor activation (Fig. 6 D). The allosteric signal originates
at residues T195 and F193 in ECL2, which corresponds to
the transient agonist (and allosteric modulator)-binding
site in M2-AcR. A major portion of the allosteric signal
then propagates to the IC ends of TM3 and TM6, which
contain the engineered Zn2þ-binding site, a positive allo-
steric modulator in b2AR. These results provide an under-
standing of the mechanism of allosteric communication in
class A GPCRs. Several residues in the ligand-binding or-
thosteric site allosterically communicate with the G-protein
interface in the intermediate state. We observed that these
residues play a key role in allosteric communication. In
addition, our analysis showed that mutations that affectBiophysical Journal 107(2) 422–434the ligand efficacy, but not the binding affinity, are hub res-
idues or located near hub residues in the allosteric commu-
nication pipelines. Thus, our findings provide insight into
the role of such mutations, which has hitherto been unex-
plained, and the resulting information can now be used to
stabilize the receptor in specific signaling states. Since
many class A GPCRs have structural homology, these re-
sults could also provide insight into other class A GPCRs.SUPPORTING MATERIAL
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